Oral Solid Dosage Pharmaceutical Formulation Market Outlook 2026–2035: Growth Drivers and Industry Forecast
Uncover key drivers, emerging technologies, and competitive movements shaping the oral solid dosage pharmaceutical formulation market from 2026–2035 with trusted insights from The Business Research Company
What size range is anticipated for the Oral Solid Dosage Pharmaceutical Formulation Market from 2026 to 2030?
The oral solid dosage pharmaceutical formulation market has experienced robust growth recently. This market is projected to expand from $653.26 billion in 2025 to $692.14 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.0%. Historically, this expansion has been driven by factors such as the broad adoption of oral drug delivery methods, a well-developed manufacturing infrastructure for tablets and capsules, an increasing incidence of chronic diseases, the economic efficiency of oral solid dosage forms, and extensive regulatory understanding of oral formulations.
The oral solid dosage pharmaceutical formulation market is anticipated to experience substantial expansion over the coming years. This market is projected to reach $846.38 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.2%. Several factors are expected to drive this growth during the forecast period, including a heightened demand for extended-release oral drugs, an increased emphasis on patient compliance and ease of use, the broadening scope of pharmaceutical outsourcing and CDMO services, a surge in worldwide generic drug manufacturing, and advancements in excipients and formulation innovations. Key trends anticipated for this period encompass a greater uptake of controlled and modified-release drug forms, an increasing preference for user-friendly oral solid formats, the expansion of production for both generic and branded solid dosages, a heightened concentration on formulations with high bioavailability, and a move towards more cost-effective and scalable oral dosage manufacturing processes.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15626&type=smp
What Drivers Are Affecting Demand In The Oral Solid Dosage Pharmaceutical Formulation Market?
The rising incidence of chronic diseases is anticipated to boost the expansion of the oral solid dosage pharmaceutical formulation market in the future. These are defined as health conditions that are long-lasting, usually enduring for at least three months. Their increase is attributed to an aging populace, inactive lifestyles, inadequate diets, environmental influences, and better diagnostic capabilities. Oral solid dosage pharmaceutical formulations are crucial for managing chronic diseases and promoting patient compliance with long-term treatments, given their convenience, stability, and accurate dosing. As an illustration, in February 2024, the World Health Organization, an intergovernmental body based in Switzerland, predicted more than 35 million new cancer cases by 2050, which signifies a 77% rise from the estimated 20 million cases in 2022. Consequently, the growing occurrence of chronic diseases stimulates the expansion of the oral solid dosage pharmaceutical formulation market.
Which Segments Are Gaining Traction In The Oral Solid Dosage Pharmaceutical Formulation Market?
The oral solid dosage pharmaceutical formulation market covered in this report is segmented –
1) By Dosage Form: Tablets, Capsules, Powders And Granules, Lozenges And Pastilles, Gummies
2) By Mechanism: Controlled-Release, Immediate-Release, Delayed-Release
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies, Hypermarkets Or Supermarkets
4) By End-User: Large-Size Companies, Medium And Small-Size Companies, Other End-Users
Subsegments:
1) By Tablets: Immediate-Release Tablets, Extended-Release Tablets, Controlled-Release Tablets, Effervescent Tablets, Chewable Tablets, Sublingual Tablets
2) By Capsules: Hard Gelatin Capsules, Soft Gel Capsules, Liquid-Filled Capsules, Delayed-Release Capsules
3) By Powders And Granules: Oral Powders (Reconstitution), Granules (Oral Suspension Or Dispersible Granules)
4) By Lozenges And Pastilles: Medicinal Lozenges, Herbal Lozenges, Sugar-Free Lozenges, Pastilles ( Throat Or Cough Relief)
5) By Gummies: Vitamin Gummies, Herbal And Nutritional Supplement Gummies, Pharmaceutical Gummies ( Pain Relief Or Sleep Aids)
Which Trends Are Guiding The Evolution Of The Oral Solid Dosage Pharmaceutical Formulation Market?
Leading firms within the Oral Solid Dosage (OSD) pharmaceutical market are prioritizing the creation of novel solutions, including fixed dose combinations, to boost effectiveness, patient adherence, and overall safety. An FDC, or fixed dose combination, is a medicine comprising two or more active pharmaceutical ingredients merged into one dosage form, aiming to streamline therapy and increase patient compliance. As an illustration, in February 2025, the Japanese pharmaceutical firm Ono Pharmaceutical Co. Ltd. obtained U.S. Food and Drug Administration (FDA) approval for its Journavex (suzetrigine) 50 mg oral tablets, intended for managing moderate to severe acute pain in adult patients. This medication functions by selectively blocking NaV1.8 sodium channels situated in the peripheral nervous system, thereby interrupting pain signals before their transmission to the brain, which provides effective pain management free from addiction potential. Studies in clinical settings revealed substantial reductions in pain levels relative to placebo, alongside a generally acceptable safety profile featuring minor adverse effects like itching and muscle spasms.
Who Are The Top-Performing Companies In The Oral Solid Dosage Pharmaceutical Formulation Market In Recent Years?
Major companies operating in the oral solid dosage pharmaceutical formulation market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc., Novartis AG, Hoffman-La-Roche Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim GmbH, Gilead Sciences, Amgen Inc., Teva Pharmaceuticals, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Biogen Inc., Lonza Group, Catalent Inc., Ashland Inc., Piramal Pharma Solutions, Jubilant Pharmova, CordenPharma International
Access The Complete Report For Deeper Market Insights:
Which Region Currently Holds The Largest Share Of The Oral Solid Dosage Pharmaceutical Formulation Market?
North America was the largest region in the oral solid dosage pharmaceutical formulation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral solid dosage pharmaceutical formulation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Oral Solid Dosage Pharmaceutical Formulation Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=15626&type=smp
Browse Through More Reports Similar to the Global Oral Solid Dosage Pharmaceutical Formulation Market 2026, By The Business Research Company
Oral Solid Dosage Pharmaceutical Formulation Market Report 2026
Oral Solid Dosage Contract Manufacturing Market Report 2026
Drug Formulation Market Report 2026
https://www.thebusinessresearchcompany.com/report/drug-formulation-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
